Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

a study on Hidradenitis Suppurativa

Summary

Eligibility
for people ages 10 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Haley B Naik, MD, MHSc, FAAD
Headshot of Haley B Naik
Haley B Naik

Description

Summary

Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

Keywords

Hidradenitis Suppurativa, Hidradenitis

Eligibility

You can join if…

Open to people ages 10 years and up

  1. Male or female ≥ 10 years of age
  2. Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS
  3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

You CAN'T join if...

  1. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.

Location

  • UCSF accepting new patients
    San Francisco California 94115 United States

Lead Scientist at UCSF

  • Haley B Naik, MD, MHSc, FAAD
    Hidradenitis Suppurativa (HS) is a prevalent and debilitating disease predominating in women and minorities. Despite its prevalence and morbidity, the biology of HS is poorly understood, thus limiting the development of effective therapies.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT04115566
Study Type
Observational [Patient Registry]
Participants
Expecting 3000 study participants
Last Updated
Contact us about this trial